Rationel behandling af ukontrollable, livstruende blødninger med anvendelse af rekombinant faktor VIIa

Jakob Stensballe; Stefan Lethagen; Freddy Lippert; Pär Johansson

Rationel behandling af ukontrollable, livstruende blødninger med anvendelse af rekombinant faktor VIIa

Jakob Stensballe^*, Stefan Lethagen, Freddy Lippert, Pär Johansson

^*Corresponding author af dette arbejde

5 Citationer (Scopus)

Abstract

We present a standardised treatment algorithm used to treat life-threatening haemorrhage (LTH) due to trauma, surgery, or delivery at Rigshospitalet, Copenhagen University Hospital, Balanced transfusion therapy and infusion of fibrinogen must precede recombinant factor Vila (rFVIIa) treatment. rFVIIa is indicated in patients with uncontrollable LTH (> 1 blood component per 10 kg of whole body weight per hour) despite surgical treatment and adequately balanced transfusion. We recommend rFVIIa at a dose of 100 μ g/kg. The dosage recommendation is not evidence-based. A thorough, prospective surveillance program to monitor the treatment's efficacy and safety is therefore mandatory. The Blood Bank services, guides and coordinates the treatment.

Bidragets oversatte titel	Recombinant factor VIIa treatment in patients with uncontrollable, life-threating haemorrhage, an algorithm-based approach
Originalsprog	Dansk
Tidsskrift	Ugeskrift for Laeger
Vol/bind	167
Udgave nummer	25-31
Sider (fra-til)	2756-2759
Antal sider	4
ISSN	0041-5782
Status	Udgivet - 20 jun. 2005

Andre filer og links

Link to publication in Scopus

Citationsformater

@article{0051f655207f49b68d95b6a9acd89d77,

title = "Rationel behandling af ukontrollable, livstruende bl{\o}dninger med anvendelse af rekombinant faktor VIIa",

abstract = "We present a standardised treatment algorithm used to treat life-threatening haemorrhage (LTH) due to trauma, surgery, or delivery at Rigshospitalet, Copenhagen University Hospital, Balanced transfusion therapy and infusion of fibrinogen must precede recombinant factor Vila (rFVIIa) treatment. rFVIIa is indicated in patients with uncontrollable LTH (> 1 blood component per 10 kg of whole body weight per hour) despite surgical treatment and adequately balanced transfusion. We recommend rFVIIa at a dose of 100 μ g/kg. The dosage recommendation is not evidence-based. A thorough, prospective surveillance program to monitor the treatment's efficacy and safety is therefore mandatory. The Blood Bank services, guides and coordinates the treatment.",

author = "Jakob Stensballe and Stefan Lethagen and Freddy Lippert and P{\"a}r Johansson",

year = "2005",

month = jun,

day = "20",

language = "Dansk",

volume = "167",

pages = "2756--2759",

journal = "Ugeskrift for Laeger",

issn = "0041-5782",

publisher = "Almindelige Danske Laegeforening",

number = "25-31",

}

TY - JOUR

T1 - Rationel behandling af ukontrollable, livstruende blødninger med anvendelse af rekombinant faktor VIIa

AU - Stensballe, Jakob

AU - Lethagen, Stefan

AU - Lippert, Freddy

AU - Johansson, Pär

PY - 2005/6/20

Y1 - 2005/6/20

N2 - We present a standardised treatment algorithm used to treat life-threatening haemorrhage (LTH) due to trauma, surgery, or delivery at Rigshospitalet, Copenhagen University Hospital, Balanced transfusion therapy and infusion of fibrinogen must precede recombinant factor Vila (rFVIIa) treatment. rFVIIa is indicated in patients with uncontrollable LTH (> 1 blood component per 10 kg of whole body weight per hour) despite surgical treatment and adequately balanced transfusion. We recommend rFVIIa at a dose of 100 μ g/kg. The dosage recommendation is not evidence-based. A thorough, prospective surveillance program to monitor the treatment's efficacy and safety is therefore mandatory. The Blood Bank services, guides and coordinates the treatment.

AB - We present a standardised treatment algorithm used to treat life-threatening haemorrhage (LTH) due to trauma, surgery, or delivery at Rigshospitalet, Copenhagen University Hospital, Balanced transfusion therapy and infusion of fibrinogen must precede recombinant factor Vila (rFVIIa) treatment. rFVIIa is indicated in patients with uncontrollable LTH (> 1 blood component per 10 kg of whole body weight per hour) despite surgical treatment and adequately balanced transfusion. We recommend rFVIIa at a dose of 100 μ g/kg. The dosage recommendation is not evidence-based. A thorough, prospective surveillance program to monitor the treatment's efficacy and safety is therefore mandatory. The Blood Bank services, guides and coordinates the treatment.

UR - http://www.scopus.com/inward/record.url?scp=21444459221&partnerID=8YFLogxK

M3 - Tidsskriftartikel

C2 - 16014259

AN - SCOPUS:21444459221

SN - 0041-5782

VL - 167

SP - 2756

EP - 2759

JO - Ugeskrift for Laeger

JF - Ugeskrift for Laeger

IS - 25-31

ER -

Rationel behandling af ukontrollable, livstruende blødninger med anvendelse af rekombinant faktor VIIa

Abstract

Andre filer og links

Fingeraftryk

Citationsformater